FI951357A0 - Pharmaceutical compositions for sustained release of trimetazidine after oral administration - Google Patents

Pharmaceutical compositions for sustained release of trimetazidine after oral administration

Info

Publication number
FI951357A0
FI951357A0 FI951357A FI951357A FI951357A0 FI 951357 A0 FI951357 A0 FI 951357A0 FI 951357 A FI951357 A FI 951357A FI 951357 A FI951357 A FI 951357A FI 951357 A0 FI951357 A0 FI 951357A0
Authority
FI
Finland
Prior art keywords
trimetazidine
pharmaceutical compositions
oral administration
sustained release
liberation
Prior art date
Application number
FI951357A
Other languages
Finnish (fi)
Swedish (sv)
Other versions
FI116881B (en
FI951357A (en
Inventor
De Barochez Bruno Huet
Patrick Genty
Alain Cuine
Original Assignee
Adir
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adir filed Critical Adir
Publication of FI951357A0 publication Critical patent/FI951357A0/en
Publication of FI951357A publication Critical patent/FI951357A/en
Application granted granted Critical
Publication of FI116881B publication Critical patent/FI116881B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Compsn. for prolonged liberation of trimetazidine (II) or its salts, uses a polymer insoluble in water and a plasticiser to control liberation.
FI951357A 1994-03-24 1995-03-22 Pharmaceutical compositions for sustained release of trimetazidine after oral administration FI116881B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9403434 1994-03-24
FR9403434A FR2717687B1 (en) 1994-03-24 1994-03-24 Pharmaceutical compositions for the sustained release of trimetazidine after oral administration.

Publications (3)

Publication Number Publication Date
FI951357A0 true FI951357A0 (en) 1995-03-22
FI951357A FI951357A (en) 1995-09-25
FI116881B FI116881B (en) 2006-03-31

Family

ID=9461361

Family Applications (1)

Application Number Title Priority Date Filing Date
FI951357A FI116881B (en) 1994-03-24 1995-03-22 Pharmaceutical compositions for sustained release of trimetazidine after oral administration

Country Status (15)

Country Link
EP (1) EP0673649B1 (en)
JP (1) JP3017040B2 (en)
CN (1) CN1056057C (en)
AT (1) ATE216583T1 (en)
AU (1) AU684893B2 (en)
CA (1) CA2145248C (en)
DE (1) DE69526467T2 (en)
DK (1) DK0673649T3 (en)
ES (1) ES2176296T3 (en)
FI (1) FI116881B (en)
FR (1) FR2717687B1 (en)
NO (1) NO306450B1 (en)
NZ (1) NZ270791A (en)
PT (1) PT673649E (en)
ZA (1) ZA952418B (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2802424B1 (en) * 1999-12-17 2002-02-15 Adir MATRIX TABLET FOR THE EXTENDED RELEASE OF TRIMETAZIDINE AFTER ORAL ADMINISTRATION
PT1195160E (en) * 2000-10-05 2009-12-07 Usv Ltd Sustained release trimetazidine pharmaceutical compositions and a method of their preparation
FR2818549B1 (en) * 2000-12-26 2003-02-07 Servier Lab SOLID THERMOFORMABLE PHARMACEUTICAL COMPOSITION FOR THE CONTROLLED RELEASE OF TRIMETAZIDINE
EP1448173A2 (en) * 2001-11-21 2004-08-25 Themis Laboratories Private Limited A process for manufacture of a sustained release pharmaceutical composition containing microbeads of trimetazidine dihydrochloride
FR2885807B1 (en) * 2005-05-18 2008-05-16 Mg Pharma SOLID PHARMACEUTICAL COMPOSITION WITH PROLONGED RELEASE OF 1- (2,3,4-TRIMETHOXYBENZYL) PIPERAZINE, AND PREPARATION METHOD
WO2007116243A2 (en) * 2006-04-10 2007-10-18 Mintails Limited Method for treating fibromyalgia and related conditions
EP2200591A2 (en) 2007-09-11 2010-06-30 Ranbaxy Laboratories Limited Controlled release pharmaceutical dosage forms of trimetazidine
EP2389167A2 (en) 2009-01-20 2011-11-30 Micro Labs Limited Modified release solid pharmaceutical compositions of trimetazidine and process thereof
ES2567722T3 (en) * 2009-01-30 2016-04-26 Lupin Limited Trimetazidine pharmaceutical compositions
TR201001902A2 (en) 2010-03-12 2011-04-21 Ali̇ Rai̇f İlaç Sanayi̇ Ve Ti̇caret A.Ş. Trimetazidine tablets with extended release
ES2508490T3 (en) 2010-05-04 2014-10-16 Sanovel Ilaç Sanayi Ve Ticaret Anonim Sirketi Formulation of trimetazidine with different release profiles
EP2386302A1 (en) 2010-05-11 2011-11-16 Ranbaxy Laboratories Limited A controlled release pharmaceutical dosage form of trimetazidine and processes for the preparation thereof
BG1345U1 (en) * 2010-05-20 2010-08-31 "Адифарм" Ад Modified-release pharmaceutical formulation
EP2491930A1 (en) 2011-02-25 2012-08-29 Deva Holding Anonim Sirketi Pharmaceutical combination of betahistine and trimetazidine
CN102133195A (en) * 2011-03-17 2011-07-27 王国栋 Trimetazidine dihydrochloride sustained control release pellet and preparation method thereof
CN102319225B (en) * 2011-09-23 2013-04-03 广州白云山光华制药股份有限公司 Trimetazidine hydrochloride sustained release tablet and preparation method thereof
FR2986431B1 (en) * 2012-02-03 2017-03-17 Servier Lab PROLONGED RELEASE OF TRIMETAZIDINE PHARMACEUTICAL COMPOSITION, PROCESS FOR THE PRODUCTION THEREOF AND USE IN THERAPEUTIC TREATMENTS
CN102764261A (en) * 2012-07-30 2012-11-07 沈阳药科大学 Oral composition controlling release of trimetazidine dihydrochloride and preparation method of oral composition
CN103565751A (en) * 2013-10-17 2014-02-12 广州帝奇医药技术有限公司 Long-acting sustained-release pellet and preparation method thereof
US20190381034A1 (en) * 2018-06-14 2019-12-19 Ming Fang Pharmaceutical composition and method for acute on chronic liver failure and related liver diseases
CN110237053A (en) * 2019-07-26 2019-09-17 湖北欣泽霏药业有限公司 A kind of trimetazidine hydrochloride sustained-release pellet and preparation method thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2490963B1 (en) * 1980-09-30 1986-04-18 Science Union & Cie NOVEL THERAPEUTIC COMPOSITION WITH ANTI-ISCHEMIC ACTION CONTAINING TRIMETHOXY 2, 3, 4-BENZYL 1-PIPERAZINE
DE3686275T2 (en) * 1985-01-11 1993-03-18 Teijin Ltd PREPARED PRODUCTS WITH DELAYED RELEASE.
JPH0625055B2 (en) * 1985-03-18 1994-04-06 日本ケミフア株式会社 Persistent tablets
US5260066A (en) * 1992-01-16 1993-11-09 Srchem Incorporated Cryogel bandage containing therapeutic agent
US5417983A (en) * 1992-02-19 1995-05-23 Sagami Chemical Research Center Drug release controlling material responsive to changes in temperature

Also Published As

Publication number Publication date
FR2717687A1 (en) 1995-09-29
DE69526467T2 (en) 2002-12-05
NO951110D0 (en) 1995-03-23
DE69526467D1 (en) 2002-05-29
AU1502995A (en) 1995-10-05
EP0673649B1 (en) 2002-04-24
CN1124140A (en) 1996-06-12
PT673649E (en) 2002-08-30
FI116881B (en) 2006-03-31
ATE216583T1 (en) 2002-05-15
CN1056057C (en) 2000-09-06
JPH07258086A (en) 1995-10-09
NO951110L (en) 1995-09-25
CA2145248C (en) 2004-01-06
CA2145248A1 (en) 1995-09-25
DK0673649T3 (en) 2002-08-05
ZA952418B (en) 1995-12-18
EP0673649A1 (en) 1995-09-27
JP3017040B2 (en) 2000-03-06
NO306450B1 (en) 1999-11-08
FI951357A (en) 1995-09-25
ES2176296T3 (en) 2002-12-01
FR2717687B1 (en) 1996-06-14
NZ270791A (en) 1996-07-26
AU684893B2 (en) 1998-01-08

Similar Documents

Publication Publication Date Title
FI951357A0 (en) Pharmaceutical compositions for sustained release of trimetazidine after oral administration
AU7534087A (en) Sustained release pharmaceutical compositions in oral dosage form
PT781550E (en) BIOADHESIVE PHARMACEUTICAL COMPOSITION FOR THE CONTROLLED LIBERATION OF ACTIVE PRINCIPLES
DK0510404T3 (en) Gastroresistant pharmaceutical formulations for oral administration containing bile acid salts
FR2761266B1 (en) PHARMACEUTICAL COMPOSITION FORMED BY WET GRANULATION FOR THE ORAL ADMINISTRATION OF A DERIVATIVE OF N-PIPERIDINO-3- PYRAZOLECARBOXAMIDE, ITS SALTS AND THEIR SOLVATES
ATE397441T1 (en) MELTS EXTRUDED ORAL HYDROMORPHONE FORMULATIONS
TR200101262T2 (en) Prolonged-release ranolazine formulations
NO20000284D0 (en) Tannic acid polymer compositions for controlled release of pharmaceutical agents, especially in the oral cavity
CA2207835A1 (en) New derivatives of 3-(piperid-4-yl) 1,2-benzisoxazole and 3-(piperazin-4-yl) 1,2-benzisoxazole, their preparation processes and the pharmaceutical compositions they contain
DE68901390D1 (en) ORAL COMPOSITION AGAINST TARTAR.
BG106927A (en) Matrix tablet for prolonged release of trimetazidine after oral administration
ZA973495B (en) Matrix tablet allowing the prolonged release of the sodium salt of tianeptine after administration by the oral route.
NZ234211A (en) Recompressed sustained release oral pharmaceutical composition containing water sensitive pharmaceutical agents, cellulose polymer and a lubricant
ES2053528T3 (en) PHARMACEUTICAL COMPOSITION THAT INCLUDES A MEDICINAL PRODUCT AND A POLYMER INFLATABLE IN WATER.
AU570446B2 (en) Dipyridamole controlled release compositon
AR029631A1 (en) USE OF A BENZO DERIVATIVE [D] (1,3) -OXAZIN-2-ONA TO PREPARE A MEDICINAL PRODUCT AND A PHARMACEUTICALLY USEFUL KIT ADAPTED FOR DAILY ORAL ADMINISTRATION

Legal Events

Date Code Title Description
FG Patent granted

Ref document number: 116881

Country of ref document: FI

MA Patent expired